Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

BACKGROUND: The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR(+)) breast cancer refractory to letrozole or anastrozole. The safety and efficacy of anticancer treatments may be...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Noguchi, Shinzaburo, Masuda, Norikazu, Iwata, Hiroji, Mukai, Hirofumi, Horiguchi, Jun, Puttawibul, Puttisak, Srimuninnimit, Vichien, Tokuda, Yutaka, Kuroi, Katsumasa, Iwase, Hirotaka, Inaji, Hideo, Ohsumi, Shozo, Noh, Woo-Chul, Nakayama, Takahiro, Ohno, Shinji, Rai, Yoshiaki, Park, Byeong-Woo, Panneerselvam, Ashok, El-Hashimy, Mona, Taran, Tetiana, Sahmoud, Tarek, Ito, Yoshinori
Format: Artigo
Idioma:Inglês
Publicat: Springer Japan 2013
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4210660/
https://ncbi.nlm.nih.gov/pubmed/23404211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-013-0444-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars